Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andrew Grigg

Showing results (101-110 of 132) with videos related to

Pageof 14
Sort By:
Leukemia & Lymphoma|May 22, 2014
An imatinib-only window followed by imatinib and chemotherapy for Philadelphia chromosome-positive acute leukemia: long-term results of the CMLALL1 trialJason D Lickliter, Kerry Taylor, Jeff Szer, et al.
American Journal of Hematology|February 1, 2014
A phase III randomized trial of high-dose CEOP + filgrastim versus standard-dose CEOP in patients with non-Hodgkin lymphoma: 10-year follow-up data: Australasian Leukaemia and Lymphoma Group (ALLG) NHL07 trialMark Hertzberg, Jane Palfrey Matthews, Janey Malka Stone, et al.
British Journal of Haematology|July 18, 2020
Ibrutinib for central nervous system lymphoma: the Australasian Lymphoma Alliance/MD Anderson Cancer Center experienceKatharine L Lewis, Collin K Chin, Kate Manos, et al.
Blood|July 16, 2008
A multicenter prospective phase 2 randomized study of extracorporeal photopheresis for treatment of chronic graft-versus-host diseaseMary E D Flowers, Jane F Apperley, Koen van Besien, et al.
The Journal of Antimicrobial Chemotherapy|August 14, 2016
Safety, clinical effectiveness and trough plasma concentrations of intravenous posaconazole in patients with haematological malignancies and/or undergoing allogeneic haematopoietic stem cell transplantation: off-trial experienceWirawan Jeong, Peter Haywood, Naranie Shanmuganathan, et al.
Blood|July 17, 2004
Real-time quantitative PCR analysis can be used as a primary screen to identify patients with CML treated with imatinib who have BCR-ABL kinase domain mutationsSusan Branford, Zbigniew Rudzki, Ian Parkinson, et al.
British Journal of Haematology|March 14, 2024
Infection risk and antimicrobial prophylaxis in bendamustine-treated patients with indolent non-Hodgkin lymphoma: An Australasian Lymphoma Alliance studyKate Manos, Leonid Churilov, Andrew Grigg, et al.
Leukemia & Lymphoma|August 27, 2020
Primary prophylaxis with G-CSF may improve outcomes in patients with newly diagnosed stage III/IV Hodgkin lymphoma treated with brentuximab vedotin plus chemotherapyDavid Straus, Graham Collins, Jan Walewski, et al.
Clinics in Liver Disease|July 4, 2019
Screening and Prophylaxis to Prevent Hepatitis B Reactivation: Other Populations and Newer AgentsJoe Sasadeusz, Andrew Grigg, Peter D Hughes, et al.
Haematologica|October 14, 2011
Results of the APML3 trial incorporating all-trans-retinoic acid and idarubicin in both induction and consolidation as initial therapy for patients with acute promyelocytic leukemiaHarry Iland, Ken Bradstock, John Seymour, et al.
Pageof 14

Showing results (101-110 of 132) with videos related to

Sort By:
Pageof 14
Leukemia & Lymphoma|May 22, 2014
An imatinib-only window followed by imatinib and chemotherapy for Philadelphia chromosome-positive acute leukemia: long-term results of the CMLALL1 trialJason D Lickliter, Kerry Taylor, Jeff Szer, et al.
American Journal of Hematology|February 1, 2014
A phase III randomized trial of high-dose CEOP + filgrastim versus standard-dose CEOP in patients with non-Hodgkin lymphoma: 10-year follow-up data: Australasian Leukaemia and Lymphoma Group (ALLG) NHL07 trialMark Hertzberg, Jane Palfrey Matthews, Janey Malka Stone, et al.
British Journal of Haematology|July 18, 2020
Ibrutinib for central nervous system lymphoma: the Australasian Lymphoma Alliance/MD Anderson Cancer Center experienceKatharine L Lewis, Collin K Chin, Kate Manos, et al.
Blood|July 16, 2008
A multicenter prospective phase 2 randomized study of extracorporeal photopheresis for treatment of chronic graft-versus-host diseaseMary E D Flowers, Jane F Apperley, Koen van Besien, et al.
The Journal of Antimicrobial Chemotherapy|August 14, 2016
Safety, clinical effectiveness and trough plasma concentrations of intravenous posaconazole in patients with haematological malignancies and/or undergoing allogeneic haematopoietic stem cell transplantation: off-trial experienceWirawan Jeong, Peter Haywood, Naranie Shanmuganathan, et al.
Blood|July 17, 2004
Real-time quantitative PCR analysis can be used as a primary screen to identify patients with CML treated with imatinib who have BCR-ABL kinase domain mutationsSusan Branford, Zbigniew Rudzki, Ian Parkinson, et al.
British Journal of Haematology|March 14, 2024
Infection risk and antimicrobial prophylaxis in bendamustine-treated patients with indolent non-Hodgkin lymphoma: An Australasian Lymphoma Alliance studyKate Manos, Leonid Churilov, Andrew Grigg, et al.
Leukemia & Lymphoma|August 27, 2020
Primary prophylaxis with G-CSF may improve outcomes in patients with newly diagnosed stage III/IV Hodgkin lymphoma treated with brentuximab vedotin plus chemotherapyDavid Straus, Graham Collins, Jan Walewski, et al.
Clinics in Liver Disease|July 4, 2019
Screening and Prophylaxis to Prevent Hepatitis B Reactivation: Other Populations and Newer AgentsJoe Sasadeusz, Andrew Grigg, Peter D Hughes, et al.
Haematologica|October 14, 2011
Results of the APML3 trial incorporating all-trans-retinoic acid and idarubicin in both induction and consolidation as initial therapy for patients with acute promyelocytic leukemiaHarry Iland, Ken Bradstock, John Seymour, et al.
Pageof 14